Nick Melia (@arta_semita) header
Nick Melia (@arta_semita) profile picture

Interdisciplinary systems & translational scientist; focused on severe ME Chief Research Officer, scientific advisor @ Macdonald Foundation @RenegadeRes

Joined September 2021
Nick Melia retweeted
Our bodies are colonized by trillions of viruses that we live with in homeostasis. The most diverse and abundant of these viral families are anelloviruses. A new paper from us at @MSKCancerCenter explores what happens after we *all* have been infected biorxiv.org/content/10.64898… 1/n
8
156
20
563
66,853
Nick Melia retweeted
Chronic progressive demyelination induces a microglial state with lysosomal dysfunction @NatureNeuro nature.com/articles/s41593-0…
3
32
93
3,999
Terance Tao: Imagine prescribing a drug no one understood. Medical community:
112
889
82
12,970
293,424
Nick Melia retweeted
We've been calling it mitochondrial dysfunction for decades. Turns out that term is scientifically meaningless, and it's been holding back progress in understanding how mitochondria actually work. @MitoPsychoBio and colleagues published a perspective in Nature Metabolism arguing that the language mitochondrial scientists use fails to capture what mitochondria actually are: multifunctional organelles that dynamically recalibrate across dozens of independent activities depending on what cells need. The problem starts with oversimplification. Mitochondria get reduced to the powerhouse of the cell in introductory biology. That framing suggests a single primary job: make ATP. Reality is more complex. Mitochondria synthesize steroid hormones. They produce iron-sulfur clusters required for hundreds of proteins throughout the cell. They regulate innate immunity and antiviral responses. They control programmed cell death. They generate signaling molecules that reprogram nuclear gene expression. They can transfer between cells to rescue damaged tissue. Key insight: These aren't backup functions that kick in when energy production fails. They're simultaneous, independent, cell-type-specific roles that mitochondria perform constantly. Here's why the terminology matters: When researchers measure decreased ATP production and call it mitochondrial dysfunction, they're collapsing dozens of distinct mitochondrial activities into a binary working/broken framework. That creates problems: • A mitochondrion producing less ATP might be signaling rather than failing • Different mitochondrial activities can change independently • What looks dysfunctional in one context may be adaptive in another • Cell-type differences get lost when using generic terms The paper proposes a hierarchical terminology system with five levels: 1. Cell-dependent properties: Mitochondrial characteristics that vary by cell type. Neurons, muscle cells, and immune cells contain functionally distinct mitochondrial populations adapted to tissue-specific demands. 2. Molecular features: The structural and compositional elements. Membrane potential, protein composition, lipid content, mtDNA copy number, cristae architecture. 3. Activities: Specific biochemical processes. Oxygen consumption, ATP synthesis, reactive oxygen species production, calcium buffering, metabolite synthesis. 4. Functions: The biological purposes these activities serve. Energy provision, biosynthesis, signaling, quality control, cell death regulation. 5. Behaviors: Dynamic responses over time. Fusion, fission, movement, mitophagy, biogenesis, transfer between cells. The framework distinguishes what mitochondria are made of, what they do biochemically, why they do it biologically, and how they change over time. Example of how this improves precision: Old framing: This drug causes mitochondrial dysfunction. New framing: This drug decreases complex I activity, reducing ATP synthesis capacity while increasing superoxide production at complex III, without affecting calcium handling or steroid synthesis. The second version identifies which specific mitochondrial activities change and which remain intact. That matters for predicting side effects, understanding mechanisms, and designing interventions. The malleable nature of mitochondria creates additional complexity. Mitochondrial characteristics can shift within minutes to hours in response to nutrient availability, stress, or signaling molecules. These recalibrations are often reversible and physiologically appropriate. Calling a physiological recalibration dysfunction conflates adaptation with pathology. A muscle cell's mitochondria after endurance training look different from before training. Neither state is dysfunctional. They're optimized for different demands. The perspective argues this terminology shift will improve three outcomes: Teaching: Students learn mitochondria are multifaceted organelles rather than single-purpose powerhouses, building a more accurate mental model from the start. Research progress: Specific terminology forces specific measurements. Asking which mitochondrial activities change rather than whether mitochondria are dysfunctional leads to more mechanistic studies. Interdisciplinary collaboration: Clearer language helps researchers from different fields understand exactly what aspects of mitochondrial biology are relevant to their questions. The implications extend beyond semantics. How scientists conceptualize mitochondria shapes which questions get asked, which measurements get prioritized, and how findings get interpreted. Moving from function/dysfunction binary to multidimensional assessment requires more complex experimental designs. But that complexity better matches the biological reality. Mitochondria aren't failing when they recalibrate. They're responding. Understanding which specific activities change, in which cells, under which conditions, and with what biological purpose represents the path forward for mitochondrial science.
20
170
18
697
35,858
I have seen something similar in patients with confirmed HHV-6/VZV reactivation/SARS-CoV-2 persistent infection; vagal nerve dysfunction/small fiber neuropathy flared after using MOTS-c in two of these patients I follow. There is a possible explanation (thread below;)
“I’m currently taking Reta 2 mg once a week and have been for a month now. I started MotS-c 3 MG a couple of days ago and ended up in the hospital with facial droop. They confirmed I have Bell’s palsy. Wondering if anyone has had a similar experience?
3
3
2
16
1,441
We have pathogen circulating which is a truly exemplary MAVS disruptor (SARS-CoV-2). SARS-CoV-2 targets upstream of MAVS (RIG-1 function), MAVS directly (MAVS expression/MAVS polymerisation) and downstream (TBK1 function)
1
1
99
MOTS-c can therefore reactivate type 1 IFN responses in patients with SARS-CoV-2 persistence If OP had existing long COVID (requires reta -> MOTS-c? For what?) and/or trigeminal neuralgia prior to Bell's palsy presenting itself, then I feel MOTS-c was in fact the likely trigger
2
98
Nick Melia retweeted
Rodrigues et al. show that advanced oxidation protein products (AOPPs) drive pain, anxiety, and neuroinflammation in a mouse model of MS by activating TRPA1, a key sensory receptor. Blocking AOPPs or TRPA1 reduces these effects. shorturl.at/ucJNR
1
5
29
2,776
Medicine hypersensitivity in ME/CFS 💉 I want to share our community for the sickest patients dealing with a severe form of medicine and treatment sensitivity, where even tiny crumb doses or the wrong supplement can trigger a brutal drugged/poisoned feeling + PEM crash and carry a real risk of worsening baseline. Interesting observation: almost all of these patients also seem to have screen intolerance 🤔 Severe medicine hypersensitivity + screen intolerance = possible subtype? Also interesting: none are tube fed. Maybe extreme gastroparesis is a distinct subtype of its own? I know a few tube-fed patients who only seem to have mild issues with medicine or treatment sensitivity. Very early anecdotal data and gut feeling of course, but the pattern is interesting. If you’re dealing with this kind of medicine hypersensitivity, please join below: discord.gg/zRHEK9xT3D Cc’ @RenzPolster, @DrMichaelScoma, @DafoeWhitney @JackHadfield14 @NBoydGibbins @mecfsskeptic @MedSensitivity @alexandrite113 @NeurologistMom @zagreusrevival @arta_semita @chydorina @liamsLCjourney @AntoineMECFS @renamemecfs @3eyedlambs @rhirhiarhii @PlzSolveCFS @JeffLubell_C19 @DecodeMEstudy Please share too, so patients suffering with this can find a home, some understanding, and hopefully a little hope amongst others going through the same thing. Thanks!
18
54
4
158
10,109
Why do GLP-1 drugs fail to cause fat loss in some? A mitochondrial switch ("SLC25A45") controls whether mitochondria burn fat or carbohydrate, and removing it (in mice) makes GLP-1 drugs stop working for fat loss entirely. "Mitochondrial control of fuel switching via carnitine biosynthesis," Science, Vol 391, Issue 6786, (10.1126/science.ady5532)
7
60
4
235
16,788
New data from my lab puts ketones supplements under the microscope. We explored the degree to which 1,3-butanediol (1,3-BD; an alcohol ketone precursor) and BHB (in both its natural D and L forms) impacted liver mitochondrial function in rodents. Here's the study (we paid extra to enable open access for all!): mdpi.com/2072-6643/18/4/675 Why focus on the liver? Not only is the liver the first site of handling absorbed nutrients, it's also the site of transforming 1,3-BD into BHB. We found that this process consumes a significant amount of ATP--in other words, rather than giving the liver energy (like L- and D-BHB), 1,3-BD consumes energy. Moreover, in the process of consuming energy, 1,3-BD increased the expression of pro-inflammatory cytokines in the liver. Regarding mitochondria, the "damage" from 1,3-BD appeared to be targeting complex II of the electron transport system. As a result, oxidative stress was also significantly increased (i.e., the electrons couldn't finish their journey). We aren't the first to find liver-specific harm from 1,3-BD. The D'Agostino lab recently published work finding extensive pathological changes to liver in mice fed 1,3-BD. Our work compliments this with an added focus on the mitochondria. Summary: Not all ketones are created equal.
24
35
4
188
16,697
Cardiff and Cambridge scientists studied 159 patients and found long COVID is marked by persistent activation of the lectin complement pathway. A 4-marker panel, including MASP-2/C1Inh, predicted disease with 80% accuracy. onlinelibrary.wiley.com/doi/…
5
38
4
205
5,960
"Don't bend; don't water it down; don't try to make it logical; don't edit your own soul according to the fashion... rather, follow your most intense obsessions mercilessly."
10
290
Nick Melia retweeted
Surprise! It's Aspergillus (orange) not Candida (red) we have in excess in #MEcfs vs healthy controls (59 vs 59) in this Chinese mycobiome (gut fungus) study. Nice thread with links. And from the paper... 1/2
1) 🇨🇳 A Chinese study looked at the mycobiome, the fungi living in the human body, in 59 ME/CFS patients and 59 controls. Patients had, for example, more Aspergillus and less Candida.
11
36
1
262
16,907
Happy to share our new preprint in collaboration with Dr. Zhijian James Chen’s group. We identify PI3,5P₂ as an endogenous lipid ligand for STING, essential for its oligomerization, trafficking, and signaling activation. biorxiv.org/content/10.64898…
1
14
1
84
6,315